Clinical Trials Logo

Clinical Trial Summary

The aim of the study is: - to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for efficacy of sublingual immunotherapy. - also to find if high sensitivity CRP can be an easy non-expensive test for diagnosis and follow up of allergic rhinitis patients.


Clinical Trial Description

Over the last decades the prevalence of allergic disease has steadily been rising and recent figures indicate that in the western world 10-25% of people are affected with allergic diseases ranging from food allergy, atopic dermatitis/ eczema, allergic rhinitis, hay fever to asthma. Allergic rhinitis (AR) is the most frequent allergic disease in Western Europe that interferes with school attendance and performance, with a prevalence rate of 20-30%. Very few studies of the epidemiology were done about the prevalence of allergic rhinitis in Egypt as its prevalence was 9 %. Allergic rhinitis is allergen-specific IgE-mediated inflammatory reactions which is characterized by excessive eosinophil infiltration, Th2 cytokine responses such as IL5, IL4, IL13, and mucus secretion. The prevalence of allergic rhinitis is increasing worldwide due to changes in the socioeconomic status, environmental factor, and occupational factor. AR burden on sleep and learning is substantial in children. Moreover, AR is considered a risk factor for subsequent asthma comorbidity. Allergic rhinitis is characterized by nasal congestion, itching, rhinorrhea, and sneezing, which are manifested as a consequence of inappropriate immune responses mediated by allergen specific immunoglobulin E (IgE) antibodies toward otherwise harmless antigens such as pollen and house dust mite (HDM). High-sensitivity-C-reactive protein (hs-CRP) is a well-known systemic inflammatory marker that is easy and inexpensive to measure, together with ESR, serum Ig-E and total eosinophil count are measured as laboratory markers of allergic diseases. MicroRNAs (miRNAs) are small non-coding RNA molecules that are 18-22 nucleotides long and highly conserved throughout evolution. MiRNAs play important roles in numerous disease processes such as asthma and allergic rhinitis and that differential miRNA expression can identify novel subtypes of these diseases. As approximately 150 miRNAs are detectable in the blood, differential miRNA expression patterns may serve as a molecular fingerprint that aids in disease diagnosis, characterization, and prognosis. MiRNAs may have particular clinical utility in allergic diseases. These diseases are characterized by tissue inflammation and are particularly difficult to diagnose and characterize considering that measuring releasing mediators, such as cytokines in blood which their characteristic measurement is unreliable . As a result, invasive methods (e.g., bronchoscopy and tissue biopsies) are needed to quantify inflammatory changes. It follows that miRNA expression profiling in blood and other body fluids becomes important for identifying and developing novel, non-invasive disease Biomarkers. One of the most significantly upregulated molecules was miR-223 involved in eosinophilic inflammation and associated with lower regulatory T-cell numbers. It is well known that Treg cells play an important role in development of tolerance by producing IL-10. Thus, in the future inhibition of miR-223 could be considered an adjuvant treatment. MiR-146a is one of the two members of the miR-146 miR family. It has been reported to be involved in a large number of cell activi¬ties, such as suppression of cancer growth, inhibition of inflam¬mation, regulation of the immune system and suppression of allergic inflammation. MiR-146a play a role in regulation of allergic diseases such as allergic rhinitis by modulating Treg cells. Allergen-specific immunotherapy (AIT) is currently the only known causal effective treatment of IgE-mediated allergy. Sublingual immunotherapy is a well-established allergen-specific immunotherapy and a safe and effective strategy to reorient inappropriate immune responses in allergic patients. MiR-146a may play a role in allergen immunotherapy of allergic diseases by modulating Treg cells. Also., high miR-223 expression is associated with lower regulatory T-cell numbers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04813380
Study type Interventional
Source Zagazig University
Contact
Status Completed
Phase Phase 3
Start date July 27, 2021
Completion date October 10, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05098171 - Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors Early Phase 1
Recruiting NCT05098184 - Study on TIL for the Treatment of Advanced Melanoma Early Phase 1
Recruiting NCT05098197 - Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers Early Phase 1
Completed NCT02169609 - Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma Phase 2
Completed NCT01486498 - Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy N/A
Recruiting NCT05142475 - Study on TIL for the Treatment of Advanced Breast Cancer Early Phase 1
Recruiting NCT05420922 - Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Completed NCT03388866 - Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis Phase 4
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT02406183 - Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma Phase 1
Recruiting NCT05468307 - Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors Early Phase 1
Completed NCT01863108 - Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma Phase 1
Active, not recruiting NCT03638375 - TIL and Anti-PD1 in Metastatic Melanoma Phase 1/Phase 2
Completed NCT02765243 - Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma Phase 1
Completed NCT01291381 - Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children N/A
Recruiting NCT01513109 - Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT05087745 - A Clinical Study on TIL for the Treatment of Advanced Solid Tumors Early Phase 1
Recruiting NCT05885048 - Impact of Gonadotoxic Therapies on Fertility
Withdrawn NCT01437020 - SCH708980 With and Without AmBisome for Visceral Leishmaniasis Phase 1/Phase 2